· 1dHims & Hers shares rise as company adds new weight-loss medications to platform
Zepbound, Mounjaro and liraglutide are part of the class of weight loss medications called GLP-1s, which have exploded in popularity in recent years. Hims & Hers launched a weight loss program in late 2023, but its GLP-1 offerings have evolved as the company has contended with a volatile supply and regulatory environment.
Investor's Business Daily on MSN18h
Hims Claws Back After Its Lilly-Rivaling Obesity Plan Faces An Unexpected HitchHims stock clawed higher Wednesday though analysts laid out low expectations for Him & Hers' branded tirzepatide.
Novo Nordisk said yesterday that it’s licensed a new obesity drug from The United Laboratories, a Chinese drugmaker.
The telehealth company is offering Lilly’s branded form of tirzepatide—approved for weight loss—on its site for $1,899 a ...
Hims shares gained as much as 14% in New York, their biggest gain since Feb. 19.
In the first arrangement of its kind, Eli Lilly to connect patients through telemedicine to providers of Alzheimer’s drugs.
Customers who struggle to afford the $1,000-plus list price for weight-loss drugs Zepbound and Wegovy can buy now and pay later under a partnership ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
The drug, developed by Eli Lilly and Company, targets both GIP and GLP-1 ... is safe and effective for use in children under 18 years of age," the company has said on its website. Misuse of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results